Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NICE Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while NICE Ltd trades at $100.04 (market cap $5.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.8× NICE Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | NICE | |
|---|---|---|
Market Cap | $39.89B | $5.87B |
Sector | Health | Technology |
52-Week High | $491.22 | $170.37 |
52-Week Low | $278.09 | $83.15 |
Enterprise Value | $38.15B | $5.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NICE trades at $99.74, up 1.92% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 11.82 suggesting potential undervaluation. Recent news highlights expansion in AI-powered customer experience solutions, including partnerships and AWS integration, driving positive sentiment.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include competitive pressures in the software sector and potential margin compression as revenue growth moderates. Institutional ownership trends and bullish analyst ratings support a favorable investment case, though market volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
